Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year.
InSilico Medicine Cayman TopCo's 1-Year ROIIC % for the quarter that ended in Dec. 2025 was 3.77%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
InSilico Medicine Cayman TopCo (FRA:O15) 1-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
InSilico Medicine Cayman TopCo 1-Year ROIIC % Related Terms
InSilico Medicine Cayman TopCo 1-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InSilico Medicine Cayman TopCo 1-Year ROIIC % Chart
FRA:O15 vs MSFT, ORCL, PLTR: 1-Year ROIIC % Comparison
For the Software - Infrastructure subindustry, InSilico Medicine Cayman TopCo's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InSilico Medicine Cayman TopCo 1-Year ROIIC % vs Software Industry
For the Software industry and Technology sector, InSilico Medicine Cayman TopCo's 1-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where InSilico Medicine Cayman TopCo's 1-Year ROIIC % falls into.
1-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
1-Year Incremental Invested Capital
=
( -52.987 (Dec. 2025) - -31.893 (Dec. 2024) )
/
( 28.76 (Dec. 2025) - 759.759 (Dec. 2024) )
=
-21.094
/
-730.999
=
2.89%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
InSilico Medicine Cayman TopCo (FRA:O15) has a 1-Year ROIIC % of 3.77 as of Dec. 2025. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on InSilico Medicine Cayman TopCo and its competitors. According to the industry distribution chart, InSilico Medicine Cayman TopCo ranks #1328 out of 2558 companies in the Software industry, placing it in the top 51.9%.
Is InSilico Medicine Cayman TopCo's 1-Year ROIIC % too high?
InSilico Medicine Cayman TopCo's current 1-Year ROIIC % is 3.77. The Software industry median 1-Year ROIIC % is 4.84. InSilico Medicine Cayman TopCo's value of 3.77 is 22.1% below this industry median. Based on the distribution chart, InSilico Medicine Cayman TopCo ranks #1328 out of 2558 companies in the Software industry, which is below the industry midpoint. Overall, InSilico Medicine Cayman TopCo has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does InSilico Medicine Cayman TopCo's 1-Year ROIIC % compare to MSFT and ORCL?
According to the Software industry distribution chart, InSilico Medicine Cayman TopCo ranks #1328 out of 2558 companies for 1-Year ROIIC %. This places InSilico Medicine Cayman TopCo in the lower half of its industry. The industry median 1-Year ROIIC % is 4.84. InSilico Medicine Cayman TopCo's value of 3.77 is 22.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year ROIIC % for a Software company?
The median 1-Year ROIIC % among Software companies is 4.84, based on 2,558 companies in the industry. Companies in the top quartile (top 25%) have a 1-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 1-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InSilico Medicine Cayman TopCo's current 1-Year ROIIC % of 3.77 is 22.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year ROIIC % mean?
A high 1-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on InSilico Medicine Cayman TopCo and its competitors. For the Software industry, the median 1-Year ROIIC % is 4.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InSilico Medicine Cayman TopCo's current 1-Year ROIIC % is 3.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InSilico Medicine Cayman TopCo stock overvalued right now?
InSilico Medicine Cayman TopCo (FRA:O15) has a current 1-Year ROIIC % of 3.77. The current 1-Year ROIIC % is 3.77 and 22.1% below the Software industry median of 4.84. InSilico Medicine Cayman TopCo's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year ROIIC % calculated?
1-Year ROIIC % is calculated from a company's financial statements. For InSilico Medicine Cayman TopCo (FRA:O15), the current 1-Year ROIIC % is 3.77 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
InSilico Medicine Cayman TopCo is engaged in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. It has generated multiple clinical-stage or IND-enabling assets using Pharma.AI, an AI-enabled platform that supports drug discovery and development activities. The company operates under a project-based business model, deriving revenue from out-licensing and collaboration arrangements. Geographically, the company generates revenue from multiple countries, with the majority of the revenue coming from United States.
20GF Score
Get the complete analysis for FRA:O15
1-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:O15 has been successfully added to your 
